Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Uterine Neoplasms × olaparib × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 32 Breast Neoplasms 23 Triple Negative Breast Neoplasms 16 Prostatic Neoplasms 15 Fallopian Tube Neoplasms 11 Neoplasms 8 Pancreatic Neoplasms 6 Glioma 6 Endometrial Neoplasms 6 Carcinoma, Ovarian Epithelial 6 Stomach Neoplasms 5 Small Cell Lung Carcinoma 5 Sarcoma 5 Fanconi Anemia, Complementation Group D1 5 Cholangiocarcinoma 5 Urinary Bladder Neoplasms 4 Lymphoma, Non-Hodgkin 4 Carcinoma, Non-Small-Cell Lung 4 Advanced Breast Cancer 4 Uterine Cervical Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Recurrence 3 Osteosarcoma 3 Neoplasm Metastasis 3 Medulloblastoma 3 Lung Neoplasms 3 Glioblastoma 3 Colorectal Neoplasms 3 Wilms Tumor 2 Uveal Melanoma 2

Interventions

Paclitaxel 6 Carboplatin 3 pembrolizumab 2 durvalumab 2 Radiotherapy 2 Pemetrexed 2 FANG vaccine 2 Docetaxel 2 Cisplatin 2 CP protocol 2 seribantumab 1 olaparib 1 niraparib 1 gedatolisib 1 dactolisib 1 belzutifan 1 atezolizumab 1 alovudine 1 adavosertib 1 Vitamin D 1 Trabectedin 1 Topotecan 1 TP protocol 1 Radiation 1 Proflavine 1 Poly(ADP-ribose) Polymerase Inhibitors 1 Oxaliplatin 1 Nivolumab 1 Leuprolide 1 Leucovorin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03951415 2021-04-01

DOMEC

Leiden University Medical Center

Phase 2 Unknown

Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡